Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Subcutaneous Rituximab and Intravenous Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients ("Slow Go") With Aggressive CD20-positive B-cell

Trial Profile

Subcutaneous Rituximab and Intravenous Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients ("Slow Go") With Aggressive CD20-positive B-cell

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jan 2019

At a glance

  • Drugs Bendamustine (Primary) ; Rituximab (Primary)
  • Indications B-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms B-R-ENDA; BRENDA
  • Most Recent Events

    • 12 Oct 2018 Status changed from recruiting to completed.
    • 28 Nov 2015 Planned number of patients changed from 100 to 77, according to European Clinical Trials Database record.
    • 07 Sep 2013 New source identified and integrated (European Clinical Trials Database: EudraCT2010-024004-98).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top